Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24
FINAL STATS with OVER 21 million impression on X

SHOUT OUT TO Our Ambassadors Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social

Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X

SHOUT OUT TO Our Ambassadors
Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social

GREAT 1st DAY OF #PROSCA24
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️

Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Great slides - thanks for sharing. Noted the inclusion and importance of #clinicaltrials for papillary RCC specifically.

Thank you all.
Sincerely, papillary rcc patient #kidneycancer #RenalC24

For metastatic RCC, current combo therapies have led to significant outcome improvements and durable responses. The conclusion highlights the importance of precision medicine, optimization of combination therapies, and the need for new biomarkers to improve patient outcomes
#RenalC24 🚨 #kidneyCancer

2 Million Impressions on the first ever #RenalC24
Congratulations to our Collaborators at Mirrors of Medicine
JOIN US TOMORROW for Day One of #BLADDR24
WE ARE @OncoAlert 🚨

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨

Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025

Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social

Proponents of deferred CN argue a complete pathological response in the 1ry tumor is rare, and even in cases of complete response at metastatic sites, viable tumor cells may remain in the 1ry site. Removing the primary tumor might help eliminate rapidly metastasizing clones
#RenalC24 🚨 #kidneyCancer

Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC

#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Dr. Barthelemy,
Moving forward, identifying biomarkers like KIM1 and T-effector gene expression signatures could help predict which patients are more likely to benefit from therapy. The need for predictive algorithms to assess efficacy and toxicity is clear #kidneyCancer
#RenalC24 🚨

Day 1 of #RENALC24
Dr. Axel Bex
High-risk RCC after nephrectomy and oligometastatic RCC
To operate or not? Debate on deferred cytoreductive nephrectomy

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Register:
https://buff.ly/3Z4aEt3

Day 1 🚨 #RENALC24
The KEYNOTE-564 trial: first study to do so. However, several important questions remain unresolved. Key among them is determining which patients benefit most from adjuvant therapy and which might not need it at all. #KidneyCancer

Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
High-risk RCC after nephrectomy & oligometastatic RCC
Risk assessment of post-nephrectomy patients

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

#KidneyCancer
Register:
https://buff.ly/3Z4aEt3

Day 1🚨 #RENALC24
Dr. Bernadett Szabados
Metastatic RCC

KN-564 trial is significant for demonstrating adjuvant pembrolizumab improves survival in #kidneyCancer

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

Register
https://buff.ly/3Z4aEt3